What it is — The most-studied dual stack in growth hormone research — pairing a GHRH analog with a selective GH-releaser to target two receptors on the same pathway. Why it's studied — CJC-1295 amplifies natural GH release pulses while Ipamorelin selectively triggers GH without affecting cortisol, prolactin, or appetite. The two peptides hit complementary receptors, producing synergistic IGF-1 elevation. Key research findings

• Synergistic IGF-1 elevation beyond either compound alone (Teichman et al., CJC-1295 trials)

• Ipamorelin: clean GH release without cortisol or prolactin elevation (Raun et al.)

• Preserved natural pulsatile release patterns when used in combination